PluroGen Therapeutics, Inc.
503 Broadleaf Way
Charlottesville, VA 22911
Tel: 443 994 0101
Fax: 410 990 9817
www.plurogen.com
503 Broadleaf Way
Charlottesville, VA 22911
Tel: 443 994 0101
Fax: 410 990 9817
www.plurogen.com
| News Release |
FOR IMMEDIATE RELEASE Contact: Neal G. Koller
President & CEO
11 November 2008 Board of Directors
443 994 0101
PLUROGEN THERAPEUTICS INC. SIGNS DISTRIBUTION AGREEMENT WITH
GWR Medical, INC. TO FOR THE CHRONIC WOUND AND MILITARY MARKETS
(Charlottesville, VA, 11 November 2008) – PluroGen Therapeutics, Inc. today announced the signing of a
Distribution Agreement with GWR Medical, Inc., for GWR Medical to distribute PluroGen’s’ branded burn,
wound care and OTC product lines to their network of hospitals, wound care clinics, doctors offices and
military facilities. PluroGen sales to GWR Medical are targeted to begin in Q1 2009, immediately on
PluroGen’s FDA regulatory approval.
Neal G. Koller, President & CEO of PluroGen, in making this announcement, commented that “GWR Medical
is a terrific partner for Plurogen. Their unique products are targeted squarely at the same patient
populations and product decision makers as PluroGen’s flagship product lines. GWR Medical fully
understands our customers, our markets and posses the close relationships needed to maximize success.”
In his announcement, Paul Geary, President & CEO for GWR Medical said “PluroGen provides GWR Medical
with a very synergetic and complimentary technology and products to maximize the performance of our
market leading topical oxygen products and Wound Matrix software. Together we expect to accelerate
our penetration of the burn, chronic wound and military intuitional markets.”
About PluroGen Therapeutics, Inc.
PluroGen is a skin care and wound healing company commercializing our core patent-protected gel
technology platform that provides superior and differentiated physical, bio-impact and multi-function
benefits. Our multiple technology platforms are configurable to deliver drug and non-drug compounds as
protected and advanced therapeutic and topical products for simple and complex skin care, burn and
wound healing. PluroGen’s product pipeline targets improved, protected therapies for the 6 areas of
treatment in tissue management and healing (cleansing, infection, pain, inflammation, tissue salvage,
tissue regeneration).
PluroGen’s first gel, PluroGel™, is being used initially in skin and wound cleansing products and for two
branded topical antimicrobial products, PluroGel™ Barrier Gels and PluroGel™ Barrier Dressings. PluroGel™
technology is currently in routine use at the University of Virginia Medical Center, having shown superior
results on more than 2,000 patients in two different patient populations, severe burns and chronic
wounds. The PluroGen management and operational teams, Boards and Principal Investigators are
recognized global clinical and commercial leaders in PluroGen’s target markets of burn and wound care and
in the life sciences industry.
For more information about PluroGen Therapeutics, Inc., visit the Company’s web site at www.plurogen.com.
About GWR Medical, Inc.
GWR Medical, Inc., founded in 1996, is the leading provider of Topical Oxygen Therapy (TO2™) for the
healing of chronic wounds. The company’s sales force calls on physicians to utilize GWR’s FDA approved
Topical Oxygen Therapy Devices and Therapy Protocol to treat their patients with non-healing wounds
such as diabetic ulcers, pressure sores, venous stasis ulcers, burns, trauma and post-op wounds in any
patient setting, but mostly, in the home.
The efficacy of the therapy is validated by the use of WoundMatrix, Inc.’s, WoundMatrix® Web proprietary
digital imaging software. WoundMatrix® precisely measures the exact surface area of the wound and
produces outcomes documentation for the doctors, patients and the insurance companies. WoundMatrix is
utilized and recognized by many professional, government and educational facilities as the most precise
tool available for measuring and reporting wound outcomes
For more information about GWR Medical, Inc., visit the Company’s web site at www.woundrx.com.
Statements included in this press release that are not historical in nature are "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act of 1995. The Company cautions readers that
forward-looking statements are subject to certain risks and uncertainties, which could cause actual results to
differ materially and which are identified from time to time in the Company’s reports filed with the U.S.
Securities and Exchange Commission. PluroGen Therapeutics, Inc. claims the protection of the Safe Harbor for
forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.
Information included on PluroGen Therapeutics, Inc. and GWR Medical, Inc. website is not incorporated herein by
reference or otherwise.
© PluroGen Therapeutics, Inc. 2008
President & CEO
11 November 2008 Board of Directors
443 994 0101
PLUROGEN THERAPEUTICS INC. SIGNS DISTRIBUTION AGREEMENT WITH
GWR Medical, INC. TO FOR THE CHRONIC WOUND AND MILITARY MARKETS
(Charlottesville, VA, 11 November 2008) – PluroGen Therapeutics, Inc. today announced the signing of a
Distribution Agreement with GWR Medical, Inc., for GWR Medical to distribute PluroGen’s’ branded burn,
wound care and OTC product lines to their network of hospitals, wound care clinics, doctors offices and
military facilities. PluroGen sales to GWR Medical are targeted to begin in Q1 2009, immediately on
PluroGen’s FDA regulatory approval.
Neal G. Koller, President & CEO of PluroGen, in making this announcement, commented that “GWR Medical
is a terrific partner for Plurogen. Their unique products are targeted squarely at the same patient
populations and product decision makers as PluroGen’s flagship product lines. GWR Medical fully
understands our customers, our markets and posses the close relationships needed to maximize success.”
In his announcement, Paul Geary, President & CEO for GWR Medical said “PluroGen provides GWR Medical
with a very synergetic and complimentary technology and products to maximize the performance of our
market leading topical oxygen products and Wound Matrix software. Together we expect to accelerate
our penetration of the burn, chronic wound and military intuitional markets.”
About PluroGen Therapeutics, Inc.
PluroGen is a skin care and wound healing company commercializing our core patent-protected gel
technology platform that provides superior and differentiated physical, bio-impact and multi-function
benefits. Our multiple technology platforms are configurable to deliver drug and non-drug compounds as
protected and advanced therapeutic and topical products for simple and complex skin care, burn and
wound healing. PluroGen’s product pipeline targets improved, protected therapies for the 6 areas of
treatment in tissue management and healing (cleansing, infection, pain, inflammation, tissue salvage,
tissue regeneration).
PluroGen’s first gel, PluroGel™, is being used initially in skin and wound cleansing products and for two
branded topical antimicrobial products, PluroGel™ Barrier Gels and PluroGel™ Barrier Dressings. PluroGel™
technology is currently in routine use at the University of Virginia Medical Center, having shown superior
results on more than 2,000 patients in two different patient populations, severe burns and chronic
wounds. The PluroGen management and operational teams, Boards and Principal Investigators are
recognized global clinical and commercial leaders in PluroGen’s target markets of burn and wound care and
in the life sciences industry.
For more information about PluroGen Therapeutics, Inc., visit the Company’s web site at www.plurogen.com.
About GWR Medical, Inc.
GWR Medical, Inc., founded in 1996, is the leading provider of Topical Oxygen Therapy (TO2™) for the
healing of chronic wounds. The company’s sales force calls on physicians to utilize GWR’s FDA approved
Topical Oxygen Therapy Devices and Therapy Protocol to treat their patients with non-healing wounds
such as diabetic ulcers, pressure sores, venous stasis ulcers, burns, trauma and post-op wounds in any
patient setting, but mostly, in the home.
The efficacy of the therapy is validated by the use of WoundMatrix, Inc.’s, WoundMatrix® Web proprietary
digital imaging software. WoundMatrix® precisely measures the exact surface area of the wound and
produces outcomes documentation for the doctors, patients and the insurance companies. WoundMatrix is
utilized and recognized by many professional, government and educational facilities as the most precise
tool available for measuring and reporting wound outcomes
For more information about GWR Medical, Inc., visit the Company’s web site at www.woundrx.com.
Statements included in this press release that are not historical in nature are "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act of 1995. The Company cautions readers that
forward-looking statements are subject to certain risks and uncertainties, which could cause actual results to
differ materially and which are identified from time to time in the Company’s reports filed with the U.S.
Securities and Exchange Commission. PluroGen Therapeutics, Inc. claims the protection of the Safe Harbor for
forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.
Information included on PluroGen Therapeutics, Inc. and GWR Medical, Inc. website is not incorporated herein by
reference or otherwise.
© PluroGen Therapeutics, Inc. 2008